Atorvastatin prescription before and after Percutaneous Coronary Intervention: Effects on Left Ventricular Ejection Fraction and blood circulating Pentraxin3

Abstract

Introduction: Statins can reduce risk of myocardial infarction, stroke and mortality in high risk individuals and improve clinical outcomes in patients undergoing Percutaneous Coronary Intervention (PCI). The major challenge of physicians at the emergency condition is the fact that patients are not stable and cannot take several pills, wholesale. Methods: This study was carried out on 100 patients who suffered from AMI with the early plan for primary PCI. All patients were divided to two group, randomly; fifty patients received conventional drug including Atorvastatin (80 mg/day), Aspirin (325 mg/day) and Clopidogrel (600 mg/day) at the time of admitting to the emergency and before primary-PCI; the other 50 patients take same drug regime without Atorvastatin just like the control group, before primary-PCI and a single dose Atorvastatin (80 mg/day) after primary PCI. A paired T-test was employed to study the result of PTX3 and LVEF before and after primary PCI among all patients. An independent T-test was also used for statistical analysis of the result of PTX3 value and EF after primary PCI for both drug plan intervention groups. Results: PTX3 and LVEF values in the group with Atorvastatin pre-treatment changed from 6.07 ± 2.31 ng/dL to 4.92 ± 1.98 ng/ dL and 40.8 ± 8.88 to 45 ± 6.77, respectively after primary PCI. Both mentioned indexes in the Atorvastatin post-treatment group were also changed from 5.91 ± 3.24 ng/dL to 5.37 ± 3.6 and 41.2 ± 8.66 to 44.9 ± 7.79, respectively, after primary PCI. None statistically significant difference were seen in comparison the results of both LVEF (P value = 0.946) and PTX3 (0.445) values between two groups. Conclusion: Our results indicate that Atorvastatin therapy after primary-PCI may has same beneficial effects on Cardiac functions compared with conventional drug regime before PCI.